Alnylam Pharmaceuticals (ALNY) Operating Income (2016 - 2025)
Historic Operating Income for Alnylam Pharmaceuticals (ALNY) over the last 16 years, with Q3 2025 value amounting to $368.0 million.
- Alnylam Pharmaceuticals' Operating Income rose 57848.9% to $368.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $264.7 million, marking a year-over-year increase of 24070.11%. This contributed to the annual value of -$176.9 million for FY2024, which is 3731.37% up from last year.
- Alnylam Pharmaceuticals' Operating Income amounted to $368.0 million in Q3 2025, which was up 57848.9% from -$16.2 million recorded in Q2 2025.
- In the past 5 years, Alnylam Pharmaceuticals' Operating Income ranged from a high of $368.0 million in Q3 2025 and a low of -$258.0 million during Q3 2022
- Its 5-year average for Operating Income is -$83.3 million, with a median of -$146.2 million in 2021.
- In the last 5 years, Alnylam Pharmaceuticals' Operating Income crashed by 13595.93% in 2024 and then soared by 57848.9% in 2025.
- Alnylam Pharmaceuticals' Operating Income (Quarter) stood at -$194.6 million in 2021, then increased by 3.06% to -$188.6 million in 2022, then surged by 38.28% to -$116.4 million in 2023, then increased by 9.66% to -$105.2 million in 2024, then skyrocketed by 449.93% to $368.0 million in 2025.
- Its Operating Income was $368.0 million in Q3 2025, compared to -$16.2 million in Q2 2025 and $18.1 million in Q1 2025.